Hepalink Pharmaceutical Holdings Limited (Hepalink Medicine-B) submitted the next day disclosure report to the Hong Kong Stock Exchange on September 20, 2024, disclosing the change in its shareholding. The report shows that Hepalink Medicine had 768,126,410 issued shares on September 19, 2024, with treasury shares of 750,000. On September 20, 2024, the company repurchased 70,000 common shares, reducing the issued shares to 768,056,410 and increasing the treasury shares to 820,000. The average price of the repurchase was HKD 1.238857 per share, totaling HKD 86,720. According to the report, this share repurchase has been formally authorized and approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. Hepalink Medicine confirmed that, in addition to the share repurchase, there will be no new share issuance or further sale or transfer of treasury shares from the repurchase date to October 20, 2024.

Hepalink Pharmaceutical Holdings Limited (Hepalink Medicine-B) submitted the next day disclosure report to the Hong Kong Stock Exchange on September 20, 2024, disclosing the change in its shareholding. The report shows that Hepalink Medicine had 768,126,410 issued shares on September 19, 2024, with treasury shares of 750,000. On September 20, 2024, the company repurchased 70,000 common shares, reducing the issued shares to 768,056,410 and increasing the treasury shares to 820,000. The average price of the repurchase was HKD 1.238857 per share, totaling HKD 86,720. According to the report, this share repurchase has been formally authorized and approved by the board of directors and complies with all applicable listing rules, laws, and other regulatory requirements. Hepalink Medicine confirmed that, in addition to the share repurchase, there will be no new share issuance or further sale or transfer of treasury shares from the repurchase date to October 20, 2024.